Efficiency of antiviral therapy for chronic hepatitis c in patients with undifferentiated connective tissue dysplasia


DOI: https://dx.doi.org/10.18565/epidem.2019.9.2.61-7

Orlova S.N., Baskhanova M.V.

1) Ivanovo State Medical Academy, Ministry of Health of Russia, Ivanovo, Russia; 2) Republican Clinical Center of Communicable Diseases, Groznyi, Russia
Objective. To determine the impact of undifferentiated connective tissue dysplasia (UCTD) on the efficiency of antiviral therapy (AVT) in patients with chronic hepatitis C (CHC).
Subjects and methods. The investigation enrolled 71 patients receiving AVT for CHC, who were divided into 2 groups: 1) 48 patients with signs of UCTD; 2) 23 patients without UCTD.
Results. During dual AVT, a sustained virological response (SVR) was achieved in 75 and 91.3% in Groups 1 and 2, respectively. Patients with genotype 1 were recorded to have SVR in 64% cases in Group 1 and in 84.6% in Group 2. In patients with HCV genotypes 2 and 3, the achievement of SVR was even higher: in 86.9 and 100% of cases in Groups 1 and 2, respectively.
Conclusion. The efficiency of AVT for CHC is associated with the presence of dysplastic manifestations in the patient. Dual AVT leads to SVR in 87% of the patients with chronic hepatitis C caused by HCV genotypes 2 and 3 and by UCTD and in 64% of those who have HCV genotype 1. There is 100% SVR in non-UCTD patients with HCV caused by HCV genotypes 2 and 85% SVR in those with HCV genotype 1. The presence of UCTD substantially affects the frequency and severity of adverse events occurring during AVT.
Keywords: undifferentiated connective tissue dysplasia, chronic hepatitis C, antiviral therapy
Read entire article

Literature

  1. Mukhin H.A., Abdurakhmanov D.T., Rozina T.P., Lopatkina T.N., Nikulkina E.N., Starostina E.E., Sidorova E.I. [New possibilities of antiviral therapy of chronic hepatitis C in patients with unfavorable prognostic factors]. Klinicheskaya gepatologiya 2013; (1): 28–36. (In Russ.).
  2. Znoiko O.O., Dudina K.R., Kozina A.N., Lenkova D.O., Kalinina O.V., Yushchuk N.D. [Pitfalls in the treatment of patients with chronic hepatitis C infected with genotypes 2 and 3 of the hepatitis C virus]. Infektsionnye bolezni. Novosti. Lechenie. Obuchenie 2016; (1): 108–13. (In Russ.).
  3. Sapronov G.V., Nikolaeva L.I. [New perspectives of personalized therapy for chronic viral hepatitis C]. Epidemiologiya i infektsionnye bolezni 2013; (3): 27–36. (In Russ.).
  4. Ozolinya A.Z. [Biochemical aspects of connective tissue reactivity]. Riga: Zinatne, 1986. 82 р. (In Russ.).
  5. Chemodanov V.V., Krasnova E.E. [Principles of diagnosis and tactics of accompanying children with connective tissue dysplasia] Vestnik Ivanovskoy meditsinskoy akademii 2015; 20(4): 5–14. (In Russ.).
  6. Makolkin V.I., Podzolkov V.I., Rodionov A.V., Sheyanov M.V., Podzolkov V.I., Rodionov A.V., Sheyanov M.V., Samoilenko V.V., Napalkov D.A. [Polymorphism of the clinical manifestations of connective tissue dysplasia syndrome]. Terapevticheskiy arkhiv 2004; (11): 80–83. (In Russ.).
  7. Martínez S.M., Crespo G., Navasa M., Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53(1): 325–35.
  8. Loeys B.L., Dietz H.C., Braverman A.C. The revised Ghent nosology for the Marfan symdrome J. Med. Genet. 2010; 47(7): 476–85.
  9. Ivashkin V.T., Yushchuk N.D., Maevskaya M.V. [Recommendations for the diagnosis and treatment of adult hepatitis C patients]. Rossijskу zurnal gastroenterologii, gepatologii i koloproktologii. 2013; (2): 41–70. (In Russ.).
  10. EASL Recommendations on Treatment of Hepatitis 2014. April 2014. – URL: htpp://files.easl.eu/easl-recommendations-on-trearment-of-hepatitis-C.pdf.
  11. EASL Recommendations on Treatment of Hepatitis C 2015. European Association for Study of Liver. J. Gastroenterology. 2015; 63 (1): 199–236.
  12. Desmet V.J., Gerber M., Hoofnagle J.H. Classification of chronic hepatitis: Diagnosis, grading and staging. J. of Hepatology. 1994; (19): 1513–1520.
  13. Yakovlev V.M., Glotov A.V., Yagoda A.V. [Immunopathological syndromes in hereditary connective tissue dysplasia]. Stavropol’, 2005. 234 р. (In Russ.).


About the Autors

Prof. Svetlana N. Orlova, MD, Head, Department of Infectious Diseases, Epidemiology and Dermatovenereology, Ivanovo State Medical Academy, Ministry of Health of Russia; Ivanovo, Russia; е-mail: orloff3.dok@mail.ru; ORCID: http://orcid.org/0000-0003-2485-6033
Markha V. Baskhanova, Postgraduate Student, Department of Infectious Diseases, Epidemiology and Dermatovenereology, Ivanovo State Medical Academy, Ministry of Health of Russia; Infectious Disease Physician, Republican Clinical Center of Infectious Diseases, Grozny, Russia; е-mail: marh.74@mail.ru


Similar Articles

Back to Content

Бионика Медиа